Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.66 |
| ▸ | HSP90AB1 | P08238 | 19/20 | 0.66 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13845716 | 0.89 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1 | |
| SCHEMBL3126003 | 0.89 | HSP90AA1 (0.76) | HSP90AA1HSP90AB1 | |
| SCHEMBL3527099 | 0.87 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1 | |
| SCHEMBL13845796 | 0.87 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1 | |
| SCHEMBL13050271 | 0.87 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1HSP90B1 | |
| SCHEMBL3747060 | 0.84 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1 | |
| SCHEMBL1669783 | 0.83 | HSP90AB1 (0.63) | HSP90AA1HSP90AB1 | |
| SCHEMBL3527160 | 0.83 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1 | |
| SCHEMBL3748340 | 0.80 | HSP90AA1 (0.76) | HSP90AA1HSP90AB1 | |
| SCHEMBL3124039 | 0.80 | HSP90AA1 (0.80) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | VHL, CLN6, CFTR | HSP90AA1 659/4885HSP90AB1 501/4885HSP90B1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.